PATRICK PINCHINAT: Open Payments
NPI 1295946002 · PEMBROKE PINES, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,908 in 186 payments from 17 companies in 2025. Trend: 2023 $2,377 · 2024 $2,739 · 2025 $3,908
Food & beverage: $3,803Education: $105
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 33 | $799 |
| Vanda Pharmaceuticals Inc. | 16 | $390 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $348 |
| Neurocrine BioSciences, Inc. | 13 | $327 |
| E.R. Squibb & Sons, L.L.C. | 12 | $297 |
| Alkermes, Inc. | 16 | $275 |
| Supernus Pharmaceuticals, Inc. | 17 | $258 |
| Otsuka America Pharmaceutical, Inc. | 11 | $253 |
| Lundbeck LLC | 11 | $238 |
| ABBVIE INC. | 13 | $218 |
Products named: UZEDY, REXULTI, HETLIOZ, CAPLYTA, INGREZZA, COBENFY, ARISTADA, AUSTEDO XR.
Industry payments across FL — which companies pay providers there.
